Skip to main content
Skip to footer

  • TCS ADD ™ Platforms / Article

Fast Track Implementation of eConsent: COVID-19 Paves the Way for Virtual Trials

Hilde Vanaken

Senior Industry Advisor, TCS Life Sciences and Healthcare

Priyanka Sawant

Head, TCS ADD Patient and Site Engagement

You have these already downloaded

We have sent you a copy of the report to your email again.

The COVID-19 pandemic has stalled multiple businesses and processes across the globe including clinical trials since there are critical activities that are carried out on site in-person such as informed consent. The impact is not just seen for new patients but also for existing patients who are required to provide re-consents in accordance with the COVID-19-led changes. To overcome these challenges, an expedited introduction and onboarding of an electronic consenting tool could be a solution. The virtual approach will enable sites to connect with patients without the need for in-person visits. This paper explores digital/virtual approaches to informed consent that could reinstate clinical trials and proceeds to study real-life implementation that Roche has executed to solve its remote consenting challenges for COVID-19 impacted clinical trials.

Related reading

Transparent AI in Pharmacovigilance and its Importance

White Paper | 20 Oct 2022

Standardization of Data Transfer Agreements & Automation in EDC

White Paper | 28 Sep 2022

Smart Medication for Enabling Patient Centricity

video | 19 Sep 2022

Merck renews its regulatory compliance strategy

Case Studies | 22 Aug 2022